BPH Energy Limited, together with its subsidiaries, engages in the biomedical research, and oil and gas exploration activities in Australia. It is developing HLS5, a tumor suppressor gene primarily for liver cancer; and brain anaesthesia monitoring system for use during surgeries. The company also holds a 100% interest in the EP386 and RL1 oil and gas assets located in the onshore Bonaparte basin of Western Australia and Northern Territory; and 85% interest in the petroleum exploration permit 11 asset located in the offshore Sydney basin. The company was formerly known as BioPharmica Limited. BPH Energy Limited was incorporated in 2001 and is based in North Perth, Australia.